Introduction
Mitochondrial peptides represent one of the most exciting frontiers in peptide research. Unlike the vast majority of peptides encoded by nuclear DNA, these compounds are encoded within the mitochondrial genome or are designed to specifically target mitochondria. They illuminate a previously unrecognized communication system between mitochondria and other cellular compartments, with profound implications for aging, metabolic disease, and cell survival research.
The Discovery of Mitochondria-Derived Peptides
The concept of mitochondria-derived peptides (MDPs) emerged from the unexpected discovery that the mitochondrial genome — long assumed to encode only the 13 proteins, 22 tRNAs, and 2 rRNAs required for oxidative phosphorylation — also contains small open reading frames encoding bioactive peptides. Humanin, discovered in 2001, was the first identified MDP. MOTS-c, discovered in 2015, was the second major MDP characterized. These discoveries expanded the functional landscape of the mitochondrial genome and established a new field of mitochondria-to-nucleus and mitochondria-to-circulation signaling.
MOTS-c: The Exercise Mimetic
MOTS-c (16 amino acids, encoded in the 12S rRNA gene) translocates from mitochondria to the nucleus under metabolic stress, where it inhibits the folate-methionine cycle to generate AICAR and activate AMPK. Research has documented exercise-like metabolic effects in mice including fat mass reduction, improved insulin sensitivity, and increased energy expenditure. MOTS-c plasma levels rise during exercise in humans, suggesting it is a genuine exercise-induced signal — a mitokine that communicates metabolic state systemically.
Humanin: The Neuroprotector
Humanin (21 amino acids, encoded in the 16S rRNA gene) was discovered through its ability to protect neurons against Alzheimer’s disease-related death mechanisms. Its neuroprotective effects operate through BAX inhibition (blocking mitochondrial apoptosis), gp130/IL-27Rα receptor activation, and direct amyloid-beta binding. Humanin levels decline with age and are elevated in centenarians — a potential longevity signal. Metabolic effects including insulin sensitization and anti-atherosclerotic activity have also been characterized.
SS-31 (Elamipretide): The Engineered Mitochondria Targeter
SS-31 is not mitochondria-derived but rather engineered to specifically target mitochondria by binding cardiolipin in the inner mitochondrial membrane. Its tetrapeptide sequence (D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH2) was designed with alternating aromatic and cationic residues for membrane association. SS-31 protects mitochondrial cristae structure, preserves electron transport chain efficiency, and reduces mitochondrial ROS production. Clinical trials in heart failure and Barth syndrome have demonstrated functional improvements, making it one of the most translationally advanced mitochondria-targeted research peptides.
Common Research Themes
Across MOTS-c, Humanin, and SS-31, several research themes connect: mitochondrial function preservation, protection against oxidative stress, aging-related decline in activity, and metabolic benefits in disease models. These compounds converge on the central importance of mitochondrial health in aging and disease — a thesis that connects them to the broader NAD+ and mitochondrial biology research programs.
Conclusion
Mitochondrial peptides — whether mitochondria-derived like MOTS-c and Humanin, or mitochondria-targeted like SS-31 — represent a frontier research area illuminating the central importance of mitochondrial signaling in aging, metabolism, neuroprotection, and disease. Their research profiles continue to develop rapidly as one of the most scientifically compelling areas of contemporary peptide research.